Medical device technologies company PLC Systems today announced that it has signed new distribution agreements for RenalGuard® with Girlow USA LLC, Cenas, Co. Ltd, and Pyramed Ltd., which expands the company’s reach in Mexico, Central America, and South America, as well as Turkey and the United Kingdom.
“These new distributors will enable PLC to expand the use of RenalGuard more deeply in important markets in Europe, and to continue our penetration of the growing healthcare markets in Mexico, Central America and South America,” Mark R. Tauscher, president and CEO of PLC Systems stated in the press release. “Our new partners are successful distributors in their respective markets and we believe their addition to our worldwide distributor network will help in our efforts to increase worldwide adoption of RenalGuard.”
RenalGuard is CE-marked, which means it can be sold immediately in the United Kingdom; Cenas has applied for Ministry of Health approval to market the product in Turkey; Girlow USA is registering RenalGuard for sale in Mexico, as well as on a country by country basis in Central America and South America.
In late 2011, PLC System commenced the U.S. pivotal trial of RenalGuard, which is required to secure approval from the U.S. Food & Drug Administration to market and sell RenalGuard in the United States.
For more information visit: www.plcmed.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment